AMENDMENTS TO THE CLAIMS

1. (Withdrawn, Currently Amended) ~~An inducer of~~A method for inducing a cytotoxic T cell (hereinafter, referred to as "CTL") comprising bringing peripheral lymphocyte cells into contact with a protein, wherein said protein comprises:

(i) the amino acid sequence shown in SEQ ID NO: 2;

(ii) an amino acid sequence wherein one or more amino acids are deleted, substituted and/or added in the amino acid of SEQ ID NO: 2; or

(iii) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2

wherein a cell expressing said protein is recognized by CTLs, or

(iv) wherein a partial peptide of said protein which is 8-14 amino acids long binds to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to HLA-A24 or HLA-B55 antigen.~~as an active ingredient a protein which comprises the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2~~.

2. (Currently Amended) A peptide which is 8-14 amino acids long, and is:

(a) a partial peptide of a protein, wherein the protein consists of ~~comprising~~

(i) the ~~same or substantially the same~~ amino acid sequence ~~as that~~ shown in SEQ ID NO: 2

(ii) an amino acid sequence wherein one or more amino acids are deleted, substituted and/or added in the amino acid sequence SEQ ID NO: 2; or

(iii) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2;

wherein a cell expressing said protein is recognized by CTLs; or

(b) a peptide comprising the amino acid sequence of (a) wherein the amino acid residue at position 2 is substituted by tyrosine, phenylalanine, methionine, or tryptophan, and/or the C terminal amino acid is substituted by phenylalanine, leucine, isoleucine, tryptophan, or methionine; and said peptide can bind to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to an HLA-A24 or HLA-B55 antigen.

3. (Cancelled)

4. (Currently Amended) The peptide of claim ~~3~~2, which comprises an amino acid sequence shown in any one of SEQ ID NO: 6 - 46.

5. (Cancelled)

6. (Previously Presented) An epitope peptide comprising a peptide of claim 2.

7. (Previously Presented) An inducer of CTL comprising a peptide of claim 2 as an active ingredient.

8.-11. (Cancelled)

12. (Withdrawn, Currently amended) A method for producing an antigen-presenting cell comprising the step of bringing a cell having antigen-presenting ability into contact with ~~any one of following (a) to (d) *in vitro*:~~

(a) a protein comprising:

(i) the ~~same or substantially the same~~ amino acid sequence ~~as that~~ shown in SEQ ID NO: 2;

(ii) an amino acid sequence wherein one or more amino acids are deleted, substituted, and/or added in the amino acid sequence SEQ ID NO: 2; or

(iii) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2

wherein a cell expressing said protein is recognized by CTL; or

(b) a peptide set forth in claim 2

~~(b) a nucleic acid comprising a polynucleotide encoding the protein of (a);~~

~~(c) a peptide set forth in claim 2; and~~

~~(d) a nucleic acid comprising a polynucleotide encoding the peptide of (c).~~

13. (Cancelled)

14. (Withdrawn, Currently amended) A method for inducing a CTL comprising the step of bringing peripheral lymphocyte cells into contact with ~~any one of following (a) to (d) *in vitro*:~~

(a) a protein comprising

(i) the ~~same or substantially the same~~ amino acid sequence ~~as that~~ shown in SEQ ID NO: 2;

(ii) an amino acid sequence wherein one or more amino acids are deleted, substituted, and/or added in the amino acid sequence SEQ ID NO: 2; or

(iii) an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2

wherein a cell expressing said protein is recognized by CTL; or

(b) a peptide set forth in claim 2.

~~(b) a nucleic acid comprising a polynucleotide encoding the protein of (a);~~

~~(c) a peptide set forth in claim 2; and~~

~~(d) a nucleic acid comprising a polynucleotide encoding the peptide of (c).~~

15.-18.(Cancelled)

19. (Currently Amended) A tumor marker comprising a peptide as set forth in claim 2 ~~at least 8 contiguous amino acids in the amino acid sequence of a protein comprising the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2~~.

20. (Original) The tumor marker of claim 19, which comprises at least 8 contiguous amino acids in the amino acid sequence shown in SEQ ID NO: 2.

21.- 24. (Cancelled)

25. (Currently amended) The tumor marker of ~~claim 17~~claim 19, wherein the tumor is sarcoma or renal cancer.

26. (Currently amended) A diagnostic agent for tumor comprising a tumor marker of ~~claim 17~~claim 19.

27. (New) A peptide which is 8-14 amino acids long and is

(i) a partial peptide of a protein consisting of the amino acid sequence shown in SEQ ID NO: 2; or

(ii) a peptide comprising the amino acid sequence of (i) wherein the amino acid residue at position 2 is substituted by tyrosine, phenylalanine, methionine or tryptophan, and/or the C terminal amino acid is substituted by phenylalanine, leucine, isoleucine, tryptophan or methionine,

wherein the peptide can bind to an HLA antigen in an HLA-A24 or HLA-B55 restricted manner and is recognized by CTLs when bound to HLA-A24 or HLA-B55 antigen.